Citations (47)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Yihai Liu, Mingyue Wu, Biao Xu & Lina Kang. (2021) Empagliflozin Alleviates Atherosclerosis Progression by Inhibiting Inflammation and Sympathetic Activity in a Normoglycemic Mouse Model. Journal of Inflammation Research 14, pages 2277-2287.
Read now
Read now
Taichi Minami, Akiko Kameda & Yasuo Terauchi. (2021) An evaluation of canagliflozin for the treatment of type 2 diabetes: an update. Expert Opinion on Pharmacotherapy 22:16, pages 2087-2094.
Read now
Read now
Maxim S. Petrov. (2021) Post-pancreatitis diabetes mellitus: investigational drugs in preclinical and clinical development and therapeutic implications. Expert Opinion on Investigational Drugs 30:7, pages 737-747.
Read now
Read now
Articles from other publishers (44)
Zahra Vaziri, Kiarash Saleki, Cena Aram, Parsa Alijanizadeh, Ramtin Pourahmad, Abbas Azadmehr & Naghmeh Ziaei. (2023) Empagliflozin treatment of cardiotoxicity: A comprehensive review of clinical, immunobiological, neuroimmune, and therapeutic implications. Biomedicine & Pharmacotherapy 168, pages 115686.
Crossref
Crossref
Ozlem Ozbek & Mehmet Mustafa Can. (2023) The effect of dapagliflozin use on cardiovascular outcomes in type 2 diabetic patients hospitalized with COVID-19. International Journal of Diabetes in Developing Countries.
Crossref
Crossref
Hongqin Wang, Xiaolin Liu, Qingbing Zhou, Li Liu, Zijun Jia, Yifei Qi, Fengqin Xu & Ying Zhang. (2023) Current status and emerging trends of cardiac metabolism from the past 20 years: A bibliometric study. Heliyon 9:11, pages e21952.
Crossref
Crossref
Jianpei Wen & Chen Chen. (2023) From Energy Metabolic Change to Precision Therapy: a Holistic View of Energy Metabolism in Heart Failure. Journal of Cardiovascular Translational Research.
Crossref
Crossref
Martino Deidda, Antonio Noto, Davide Firinu, Cristina Piras, William Cordeddu, Claudia Depau, Giulia Costanzo, Stefano Del Giacco, Luigi Atzori, Giuseppe Mercuro & Christian Cadeddu Dessalvi. (2023) Right Ventricular Subclinical Dysfunction in SLE Patients Correlates with Metabolomic Fingerprint and Organ Damage. Metabolites 13:7, pages 781.
Crossref
Crossref
Ze-Qi Yang, Yang-Yang Han, Fan Gao, Jia-Ye Tian, Ran Bai, Qiu-Hong Guo & Xing-Chao Liu. (2023) Shengxian decoction protects against chronic heart failure in a rat model via energy regulation mechanisms. BMC Complementary Medicine and Therapies 23:1.
Crossref
Crossref
Nilanjan Ghosh, Leena Chacko, Hiranmoy Bhattacharya, Jayalakshmi Vallamkondu, Sagnik Nag, Abhijit Dey, Tanushree Karmakar, P. Hemachandra Reddy, Ramesh Kandimalla & Saikat Dewanjee. (2023) Exploring the Complex Relationship between Diabetes and Cardiovascular Complications: Understanding Diabetic Cardiomyopathy and Promising Therapies. Biomedicines 11:4, pages 1126.
Crossref
Crossref
Bo Liang, Rui Li, Peng Zhang & Ning Gu. (2022) Empagliflozin for Patients with Heart Failure and Type 2 Diabetes Mellitus: Clinical Evidence in Comparison with Other Sodium-Glucose Co-transporter-2 Inhibitors and Potential Mechanism. Journal of Cardiovascular Translational Research 16:2, pages 327-340.
Crossref
Crossref
Sanne de Wit, Claire Glen, Rudolf A de Boer & Ninian N Lang. (2022) Mechanisms shared between cancer, heart failure, and targeted anti-cancer therapies. Cardiovascular Research 118:18, pages 3451-3466.
Crossref
Crossref
Lu Fan, Chenchen Meng, Xiaoming Wang, Yunjiao Wang, Yanyang Li, Shichao Lv & Junping Zhang. (2023) Driving force of deteriorated cellular environment in heart failure: Metabolic remodeling. Clinics 78, pages 100263.
Crossref
Crossref
Haiqiang Sang, Yiming Wan, Zhenzhou Ma, Shengye Zhang & Qiuping Zhao. (2022) Cost-effectiveness of empagliflozin for the treatment of heart failure with reduced ejection fraction in China. Frontiers in Cardiovascular Medicine 9.
Crossref
Crossref
S. G. Kanorskiy. (2022) New principles for the treatment of chronic heart failure: the phenomenon of sodium-glucose cotransporter type 2 inhibitors. Meditsinskiy sovet = Medical Council:17, pages 44-51.
Crossref
Crossref
Hengheng Dai, Haisong Li, Bin Wang, Jingjing Zhang, Ying Chen, Xuecheng Zhang, Yan Liu & Hongcai Shang. (2022) Efficacy of pharmacologic therapies in patients with acute heart failure: A network meta-analysis. Frontiers in Pharmacology 13.
Crossref
Crossref
Juexing Li, Lei Zhou & Hui Gong. (2022) New insights and advances of sodium-glucose cotransporter 2 inhibitors in heart failure. Frontiers in Cardiovascular Medicine 9.
Crossref
Crossref
Sumanth KHAKDE, Hafsa JAWAID, Farah YASMIN, Mashal BINTE ALI & Abdur REHMAN. (2022) Is there a paradigm shift in preventing diabetic heart failure? A review of SGLT2 inhibitors. Minerva Endocrinology 47:3.
Crossref
Crossref
Dominik Kurczyński, Bartosz Hudzik, Marta Jagosz, Jan Zabierowski, Jolanta Nowak, Andrzej Tomasik, Arkadiusz Badziński, Piotr Rozentryt & Mariusz Gąsior. (2022) Sodium-Glucose Cotransporter-2 Inhibitors-from the Treatment of Diabetes to Therapy of Chronic Heart Failure. Journal of Cardiovascular Development and Disease 9:7, pages 225.
Crossref
Crossref
Mahmoud Al Rifai, L. Kristin Newby, Ajith P. Nair, Arunima Misra, Joseph G. Rogers, Savitri Fedson & Salim S. Virani. (2022) SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently?. Current Atherosclerosis Reports.
Crossref
Crossref
Daria M. Keller, Natasha Ahmed, Hamza Tariq, Malsha Walgamage, Thilini Walgamage, Azad Mohammed, Jadzia Tin-Tsen Chou, Marta Kałużna-Oleksy, Maciej Lesiak & Ewa Straburzyńska-Migaj. (2022) SGLT2 Inhibitors in Type 2 Diabetes Mellitus and Heart Failure—A Concise Review. Journal of Clinical Medicine 11:6, pages 1470.
Crossref
Crossref
Yihai Liu, Jiamin Xu, Mingyue Wu, Biao Xu & Lina Kang. (2021) Empagliflozin protects against atherosclerosis progression by modulating lipid profiles and sympathetic activity. Lipids in Health and Disease 20:1.
Crossref
Crossref
Elias Daud, Offir Ertracht, Nadav Bandel, Gassan Moady, Monah Shehadeh, Tali Reuveni & Shaul Atar. (2021) The impact of empagliflozin on cardiac physiology and fibrosis early after myocardial infarction in non-diabetic rats. Cardiovascular Diabetology 20:1.
Crossref
Crossref
Søren S. Lund, Naveed Sattar, Afshin Salsali, Dietmar Neubacher & Henry N. Ginsberg. (2021) Potential contribution of haemoconcentration to changes in lipid variables with empagliflozin in patients with type 2 diabetes: A post hoc analysis of pooled data from four phase 3 randomized clinical trials. Diabetes, Obesity and Metabolism 23:12, pages 2763-2774.
Crossref
Crossref
Yaohui Jiang, Rujie Zheng & Haiqiang Sang. (2021) Cost-Effectiveness of Adding SGLT2 Inhibitors to Standard Treatment for Heart Failure With Reduced Ejection Fraction Patients in China. Frontiers in Pharmacology 12.
Crossref
Crossref
Daniele Masarone, Roberta Pacileo & Giuseppe Pacileo. (2021) Use of disease-modifying drugs in diabetic patients with heart failure with reduced ejection fraction. Heart Failure Reviews 28:3, pages 657-665.
Crossref
Crossref
Francesco Maranta, Lorenzo Cianfanelli, Carlo Gaspardone, Vincenzo Rizza, Rocco Grippo, Marco Ambrosetti & Domenico Cianflone. (2021) Cardiologist's approach to the diabetic patient: No further delay for a paradigm shift. International Journal of Cardiology 338, pages 248-257.
Crossref
Crossref
Melanie Nana, Holly Morgan & L. N. Rao Bondugulapati. (2020) Sodium-glucose co-transporter 2 inhibitors and heart failure—the present and the future. Heart Failure Reviews 26:4, pages 953-960.
Crossref
Crossref
Yihai Liu, Mingyue Wu, Jiamin Xu, Biao Xu & Lina Kang. (2021) Empagliflozin prevents from early cardiac injury post myocardial infarction in non-diabetic mice. European Journal of Pharmaceutical Sciences 161, pages 105788.
Crossref
Crossref
Giuseppe Palmiero, Arturo Cesaro, Erica Vetrano, Pia Clara Pafundi, Raffaele Galiero, Alfredo Caturano, Elisabetta Moscarella, Felice Gragnano, Teresa Salvatore, Luca Rinaldi, Paolo Calabrò & Ferdinando Carlo Sasso. (2021) Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects. International Journal of Molecular Sciences 22:11, pages 5863.
Crossref
Crossref
Ranjan Dahal, Yogesh Acharya & Debabrata Mukherjee. (2021) Sodium-Glucose Cotransporter Inhibitors in Non- Diabetic Heart Failure: A Narrative Review. Cardiovascular & Hematological Disorders-Drug Targets 21:1, pages 1-6.
Crossref
Crossref
Gerasimos Siasos, Evanthia Bletsa, Panagiota K. Stampouloglou, Stavroula A. Paschou, Evangelos Oikonomou, Vasiliki Tsigkou, Alexios S. Antonopoulos, Manolis Vavuranakis & Dimitrios Tousoulis. (2020) Novel Antidiabetic Agents: Cardiovascular and Safety Outcomes. Current Pharmaceutical Design 26:46, pages 5911-5932.
Crossref
Crossref
Gary D. Lopaschuk, Qutuba G. Karwi, Kim L. Ho, Simran Pherwani & Ezra B. Ketema. (2020) Ketone metabolism in the failing heart. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 1865:12, pages 158813.
Crossref
Crossref
Mei Qiu, Liang-Liang Ding, Miao Zhang, Jin-Hao Lin, Jin-Song Gu, Xian Zhou, Ying-Xi Tang, Xu-Bin Wei & Shu-Yan Liu. (2020) SGLT2 inhibitors for prevention of cardiorenal events in people with type 2 diabetes without cardiorenal disease: A meta-analysis of large randomized trials and cohort studies. Pharmacological Research 161, pages 105175.
Crossref
Crossref
Shinsuke Nirengi, Carmem Peres Valgas da Silva & Kristin I Stanford. (2020) Disruption of energy utilization in diabetic cardiomyopathy; a mini review. Current Opinion in Pharmacology 54, pages 82-90.
Crossref
Crossref
Mario Schubert, Sinah Hansen, Julian Leefmann & Kaomei Guan. (2020) Repurposing Antidiabetic Drugs for Cardiovascular Disease. Frontiers in Physiology 11.
Crossref
Crossref
Gilberto A. Castillo, Gustavo Aroca, Jannes Buelvas, Andrés F. Buitrago, Virgil Carballo, Juan M. Cárdenas, Efraín A. Gómez, Karen Fériz, John M. Lopera, Enrique Melgarejo, Katherine Restrepo, Juan D. Montejo, Juan B. Pinzón, Adalberto Quintero, Jorge E. Rico & Ricardo Rosero. (2020) Recomendaciones para el manejo del riesgo cardiorrenal en el paciente con diabetes mellitus tipo 2. Revista Colombiana de Cardiología 27, pages 3-22.
Crossref
Crossref
Ningjing Qian & Yaping Wang. (2019) Ketone body metabolism in diabetic and non-diabetic heart failure. Heart Failure Reviews 25:5, pages 817-822.
Crossref
Crossref
Bernard Cuenoud, Mickaël Hartweg, Jean-Philippe Godin, Etienne Croteau, Mathieu Maltais, Christian-Alexandre Castellano, André C. Carpentier & Stephen C. Cunnane. (2020) Metabolism of Exogenous D-Beta-Hydroxybutyrate, an Energy Substrate Avidly Consumed by the Heart and Kidney. Frontiers in Nutrition 7.
Crossref
Crossref
Laura J. Mereweather, Claudia N. Montes Aparicio & Lisa C. Heather. (2020) Positioning Metabolism as a Central Player in the Diabetic Heart. Journal of Lipid and Atherosclerosis 9:1, pages 92.
Crossref
Crossref
Yiquan Huang, Shaozhao Zhang, Menghui Liu, Xiangbin Zhong, Yifen Lin, Zhenyu Xiong, Yongqiang Fan, Huimin Zhou, Xiuting Sun, Yue Guo, Xingfeng Xu, Yuqi Li, Daya Yang, Xiaodong Zhuang & Xinxue Liao. (2020) Impact of RAAS Blockers on Contrast-Induced Nephropathy in Patients With Renal Insufficiency: A Meta-Analysis. Journal of Cardiovascular Pharmacology 76:6, pages 692-697.
Crossref
Crossref
Belma Turan. 2020. Biochemistry of Cardiovascular Dysfunction in Obesity. Biochemistry of Cardiovascular Dysfunction in Obesity
125
144
.
Francesco Maranta, Lorenzo Cianfanelli & Domenico Cianflone. 2021. Diabetes: from Research to Clinical Practice. Diabetes: from Research to Clinical Practice
129
152
.
Álvaro García-Ropero, Carlos G Santos-Gallego & Juan J. Badimon. (2019) The anti-inflammatory effects of SGLT inhibitors. Aging 11:16, pages 5866-5867.
Crossref
Crossref
Anastasios Tentolouris, Panayotis Vlachakis, Evangelia Tzeravini, Ioanna Eleftheriadou & Nikolaos Tentolouris. (2019) SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects. International Journal of Environmental Research and Public Health 16:16, pages 2965.
Crossref
Crossref
Álvaro García-Ropero, Ariana P. Vargas-Delgado, Carlos G. Santos-Gallego & Juan J. Badimon. (2019) Inhibition of Sodium Glucose Cotransporters Improves Cardiac Performance. International Journal of Molecular Sciences 20:13, pages 3289.
Crossref
Crossref
Vinay Garg, Subodh Verma & Kim Connelly. (2019) Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes. Progress in Cardiovascular Diseases 62:4, pages 349-357.
Crossref
Crossref